reported increased fecal uroporphyrin in two of three patients with AIP and all four patients with VP. Because our three patients were excreting high concentrations of urine PBG at the time of fecal collection, their serum PBG was probably increased. If this is the source of fecal uroporphyrin, it probably would also be seen during acute attacks of the other acute porphyrias, as has been reported for VP (12).
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HCP was excluded from the differential diagnosis in all three cases by the low proportion of fecal coproporphyrin III (2) and by the proportion of coproporphyrin I exceeding coproporphyrin III for all three cases (13) . VP is characterized by a fecal porphyrin trace in which protoporphyrin predominates (2) and was excluded because protoporphyrin was Ͻ5% of the total porphyrin in all three patients.
We therefore concluded that all three patients have AIP with increased fecal porphyrins and an increased fecal uroporphyrin fraction. The source of the uroporphyrin is probably the nonenzymatic condensation of PBG produced during the acute attack and excreted into the bile. Fecal uroporphyrin in patients excreting excess PBG could, therefore, be a feature of the acute attack in any of the three acute porphyrias.
I thank D. Blake and V. Cronin of the Royal Melbourne Hospital for performing the PBG deaminase determinations. The ultimate aim of glucose sensor construction is to provide an accurate means for the measurement of glucose concentrations in vivo as part of a closed-loop insulin delivery system. Various types of sensors (mainly those based on amperometric measurement of hydrogen peroxide generated by enzymatic oxidation of glucose) have been implanted into the subcutaneous tissue of animals (1, 2) and human subjects (3) . The researchers conducting these experiments routinely found that sensors in subcutaneous tissue had much lower sensitivities to glucose than those in buffer solutions (3, 4) .
Prevention of the Decrease in
The causes for this loss of sensitivity in vivo are not known; however, four hypotheses are frequently put forward to explain this phenomenon (3, 4) : (a) the concentrations of glucose and/or oxygen in the surrounding tissue are lower than expected; (b) proteins or other substances are adsorbed onto the outer surface of the sensor, hindering the diffusion of glucose and/or oxygen through the membrane ("membrane fouling"); (c) the activity of glucose oxidase is inhibited by an unknown, presumably low-molecular weight substance; and (d) detection of hydrogen peroxide by the platinum anode is inhibited ("electrode fouling"). Interestingly, a loss of sensitivity to glucose of similar magnitude is observed in human serum and in serum ultrafiltrate (3) . This makes the first hypothesis unlikely, provided that identical mechanisms are responsible for the inactivation of sensors in serum and in subcutaneous tissue. If it were possible to prevent sensor inactivation with a membrane placed between the electrode surface and the enzyme layer, this would provide evidence that the second and third hypotheses are of minor importance and favor, at least indirectly, the importance of the fourth hypothesis. The aim of the present study was to examine the effect of such a membrane on the sensitivity to glucose of a sensor exposed to undiluted human serum for 15 h. The membrane to be tested was from microporous polytetrafluoroethylene (PTFE). This material was chosen because of its known excellent properties in the elimination of interfering electroactive substances (5) . The sensor was a commercially available glucose macroelectrode.
Tests were performed with the amperometric flow cell and the multichannel peristaltic pump of the Biostator Glucose-Controlled Insulin Infusion System from Bayer Diagnostic. Each experiment was performed on two different instruments in parallel. The electrode of the flow cell of one instrument (platinum anode, Ag/AgCl cathClinical Chemistry 45, No. 2, 1999 ode; polarization voltage ϩ700 mV) was covered as usual with a glucose oxidase membrane (YSI 2365 glucose membrane kit; Yellow Springs Instruments Co., Inc.), whereas an additional membrane (microporous PTFE; pore size, 0.5 m; thickness, ϳ57 m; Universal Sensors) was placed into the flow cell of the other instrument between the electrode and the YSI membrane. The electrodes were kept at 32°C throughout the experiments. Current-time curves were recorded with a Linseis LS 2200 three-channel recorder). Before the start of each experiment, both flow cells were perfused overnight with phosphate-buffered saline (PBS) solution (100 mmol/L NaCl, 11.6 mmol/L NaH 2 PO 4 , and 38.4 mmol/L Na 2 HPO 4 , pH 7.4) containing 5 mmol/L glucose. The perfusion rate was kept at 1.2 mL/h during all experiments. Membrane responses to glucose or interfering substances were evaluated by registration of steady-state values.
Microporous PTFE is a gas-permeable membrane, and the vapor pressure of hydrogen peroxide allows a substantial amount of hydrogen peroxide to cross such membranes (6) . One would expect that the protons and oxygen generated by the electrochemical oxidation of hydrogen peroxide would affect sensor performance adversely, especially when a small volume of solution is trapped between the membrane and the electrode (6) . We tested the stability of sensor responses to 5 mmol/L glucose in PBS over a 48-h period. The currents were stable and decreased only slightly over time in cells with (mean value from three experiments, Ϫ6%) and without PTFE membranes (Ϫ7%). Therefore, the above mentioned constraints do not seem to limit the system in practical use. Interferences from ascorbic acid (0.1 mmol/L in PBS), uric acid (0.25 mmol/L), glutathione (0.05 mmol/L), and Lcysteine (0.05 mmol/L) at physiological concentrations did not exceed the background value (mean values from three experiments, 0.6 nA without PTFE and 0.4 nA with PTFE), irrespective of the use of microporous PTFE. This result was expected because the YSI membrane is already designed to exclude these interferences. The better interferent-eliminating effect of the PTFE membrane can be seen from the result obtained with acetaminophen. The signal from acetaminophen at a concentration in the therapeutic range (0.5 mmol/L in PBS) was 3.0 nA (background, 0.6 nA) without and 0.6 nA (background, 0.4 nA) with microporous PTFE. Similar results have been described with other membrane materials (7) (8) (9) .
For examination of the sensor responses to undiluted serum, the flow cells were first calibrated by perfusion with glucose calibrator solutions in PBS (0 -20 mmol/L). During the following night, the flow cells were perfused for 15 h with freshly prepared serum. Serum for one experiment was prepared from 100 mL of blood drawn from a healthy volunteer. The next morning, the flow cells were calibrated with serum containing defined glucose concentrations. These serum samples had been prepared the day before and stored overnight at 4°C. Finally, the flow cells were perfused with PBS for 1 h and calibrated again in PBS. All experiments were performed at room temperature. The results shown are based on six experiments. Glucose concentrations in sera were measured with a Beckman Glucose Analyzer II (Beckman Instruments) and adjusted to 5 mmol/L by addition of small volumes of 50 g/L glucose in water. For calibration of the flow cells with serum, glucose concentrations were in- (A), flow cells contain the YSI membrane, but not the microporous PTFE membrane; (B), flow cells contain the YSI and microporous PTFE membranes. F, sensitivity in PBS before incubation in serum; ᭛, sensitivity in serum; E, sensitivity in PBS after incubation in serum. All data points are means of six experiments Ϯ SE (bars).
creased by addition of calculated amounts of 200 g/L glucose. Serum glucose concentrations attained by this procedure were controlled by measurement with the Beckman Glucose Analyzer.
The sensitivity to glucose (calculated for the range 5-10 mmol/L) in phosphate buffer (pH 7.4) was 10.2 Ϯ 3.3 nA ⅐ L ⅐ mmol Ϫ1 (mean of slopes calculated from each experiment Ϯ SE; Fig. 1A) .The sensitivity to glucose after exposure to human serum for 15 h was 3.7 Ϯ 1.7 nA ⅐ L ⅐ mmol
Ϫ1
. After reexposure to buffer, the sensitivity was 8.3 Ϯ 2.0 nA ⅐ L ⅐ mmol Ϫ1 . The mean sensitivities in serum were significantly lower in serum compared with buffer before and after exposure to serum (P Ͻ0.01; one-way ANOVA). The corresponding results obtained with flow cells in which a microporous PTFE membrane was placed between the electrode surface and the YSI membrane are shown in Fig. 1B . Again, the sensitivities for glucose (calculated for 5-10 mmol/L) were similar in PBS before (1.7 Ϯ 0.4 nA ⅐ L ⅐ mmol Ϫ1 ) and after (1.3 Ϯ 0.3 nA ⅐ L ⅐ mmol Ϫ1 ) exposure to serum. However, in contrast to the experiment without the PTFE membrane, there was no decrease of sensitivity after exposure to serum (1.
. Statistically significant differences between the sensitivities in serum and in buffer before and after serum exposure could not be detected.
Exposure of unmodified glucose electrodes to human serum for 15 h decreased the sensitivity to glucose by 55%. When electrodes were subsequently perfused for 1 h with PBS, the sensitivity was restored almost completely. The decrease of sensitivity in serum was prevented when a microporous PTFE membrane was placed between the enzyme layer and the electrode surface. The observation that a membrane that protects only the platinum anode (and not the outer membrane or the enzyme layer) can prevent the loss of sensitivity clearly speaks against the importance of protein adsorption or enzyme inactivation in the loss of sensitivity. On the other hand, these results allow one to conclude indirectly, and therefore cautiously, that processes at the electrode surface that inhibit the detection of hydrogen peroxide, and that are possibly prevented by the protecting membrane, are more important. This is in accordance with the results from other authors that show that sensitivity to glucose in blood or serum is retained best in electrodes that exhibit minimum responsiveness to interfering substances (7) . From the data presented here, direct information about electrode fouling processes cannot be derived. In the beginning of the study we planned to monitor the responses of the electrodes to hydrogen peroxide before, during, and after exposure to serum. The rapid decomposition of hydrogen peroxide in serum, however, precluded this strategy. Strictly speaking, the conclusions apply only to macrosensors for glucose measurement exposed to undiluted human serum. Additional experiments are necessary for assessment of the situation with microsensors implanted into subcutaneous tissue.
